Skip to content

Solid Biosciences Inc. SLDB Restructuring Charges

Restructuring Charges at other companies

Biogen logo
BiogenBIIB
$7.9M-77.6%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
Enterprise value$634.23M+244%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestructuringCharges.

The official record: Solid Biosciences Inc.’s 10-Q, filed August 13, 2024, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s restructuring charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s restructuring charges?
Solid Biosciences Inc. (SLDB) reported restructuring charges of -$63K in Q2 2023.
How has Solid Biosciences Inc.'s restructuring charges changed year-over-year?
Solid Biosciences Inc.'s restructuring charges decreased by 104.1% year-over-year, from $1.52M to -$63K.
What does restructuring charges mean?
One-time costs from reorganizing operations, including employee severance, facility closure costs, contract termination fees, and asset relocation expenses.